Cyclin D1 expression in high-grade endometrial carcinomas - Association with histologic subtype

International Journal of Gynecological Pathology

Volumn 19, Issue 4, 2000, Pages 329-334

  Soslow, Robert A ^a,b   Shen, Peter U Fu ^a   Chung, Marilda H ^a   Isacson, Christina ^a   Baergen, Rebecca N ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b WMC   (United States)

Author keywords

Carcinoma; Cyclin D; Endometrium

Indexed keywords

CYCLIN D1;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CLINICAL ARTICLE; DISEASE ASSOCIATION; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL;

EID: 0033730454     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-200010000-00006     Document Type: Article

References (37)

1. CDK-independent activation of estrogen receptor by cyclin D1
2. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2
3. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas
4. Review. Postmenopausal unoppposed estrogens: Characteristics of use in relation to the risk of endometrial carcinoma
5. The epidemiology of serum sex hormones in postmenopausal women
6. p53 In endometrial cancer and its putative precursors: Evidence for diverse pathways of tumorigenesis
7. p53 Expression in neoplasms of the uterine corpus
8. Endometrial intraepithelial carcinoma: A distinctive lesion specifically associated with tumors displaying serous differentiation
9. p53 Gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis
10. Carcinoma of the endometrium in Norway: A histopathological and prognostic survey of a total population
11. Uterine papillary serous carcinoma: A study of 100 cases with emphasis on the prognostic significance of associated endometrial carcinoma, absence of invasion and concomitant ovarian carcinoma
12. Carcinoma of the endometrium in Norway: A histopathological and prognostic survey of a total population
13. Carcinoma of the endometrium. I: Papillary adenocarcinoma: A clinical pathological study of 46 cases
14. Endometrial papillary adenocarcinomas: Two clinicopathological types
15. Papillary carcinomas of the endometrium
16. Serous papillary carcinoma of the endometrium: A histopathological study of 22 cases
17. The CD44v6-negative phenotype in high grade uterine carcinomas correlates with aggressive histologic subtype and angioinvasion
18. Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated uterine carcinoma
19. Cyclins and cancer
20. Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation
21. Break in the bcl-1 locus is closely associated with intermediate lymphocytic lymphoma subtype
22. Immunohistochemistry of cyclin D1 in human breast cancer
23. Cyclin D1 (PRAD1) protein expression in breast cancer: Approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene
24. Expression of cyclin D1 and c-Ki-ras gene product in human epithelial ovarian tumors
25. Increased cyclin D1 expression is associated with features of malignancy and disease recurrence in ovarian tumors
26. Immunohistochemical study of cyclins D and E and cyclin dependent kinase (cdk) 2 and 4 in human endometrial carcinoma
27. Coabnormal expression of cyclin D1 and p53 protein in human uterine endometrial carcinomas
28. Announcement, FIGO stages: 1988 Revisions
29. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer: Computer-assisted image analysis (QIC score) vs. subjective grading (IRS)
30. Function of a human cyclin gene as an oncogene
31. Physical interaction of the retinoblastoma protein with human D cyclins
32. Immunocytochemical analysis of uterine papillary serous carcinomas for estrogen and progesterone receptors
33. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part II: Correlation between biochemical and immunohistochemical methods and survival
34. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: Clinical and histologic correlations
35. Cyclin D1 expression in invasive breast cancer
36. Determination of the prognostic value of cyclin D1 overexpression in breast cancer